Suicidality is a common and serious feature of anti-N-methyl-D-aspartate receptor encephalitis
We aimed to assess suicidality risk amongst people who had had anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. All people with a definitive diagnosis of anti-NMDAR encephalitis in West China Hospital between June 2012 and February 2017 were identified and their notes were retrospectively reviewed. Demographic and clinical characteristics and risk predictors for suicidality were summarized; those with suicidality were compared to those without. 17 of 133 people (13%) presented with suicidality symptoms: 7 (5%) with suicidal ideation; 8 (6%) who attempted suicide; and 2 (1.5%) who completed suicide. Median age was 27 (16–78) years, most were female [13 (76%)]. Compared with those with no suicidality, psychiatric symptoms as the initial symptoms were more frequent in those who reported suicidality (p = 0.039); insomnia, aggression, mania, depression and delusion were also more common (p < 0.05). The use of antidepressants (p < 0.001) and recurrence of encephalitis (p = 0.020) were higher in people with suicidality than in those without. Other characteristics were not significantly different in those who had suicidality and those who did not. Suicidality is a common and potentially lethal risk for people with anti-NMDAR encephalitis. Those presenting with psychiatric symptoms as the initial symptom and with insomnia, aggression, mania, depression and delusion should be carefully screened for suicidality. Closely monitoring people who have been treated with antidepressants is necessary.
KeywordsAnti-NMDAR encephalitis Suicidal rate Psychiatric symptom Predictors
We are grateful to Dr. Hai-tao Ren from the Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, China, for testing for anti-NMDAR antibodies and for technical support. We also grateful to Dr. Gail S Bell for reviewing the manuscript. JWS is based at UCLH/UCL Comprehensive Biomedical Research Centre, which receives a proportion of funding from the UK Department of Health’s National Institute for Health Research Biomedical Research Centres funding scheme. He receives support from the Dr. Marvin Weil Epilepsy Research Fund and the UK Epilepsy Society endows his current position. We thank all the subjects who participated in this study.
Compliance with ethical standards
Conflicts of interest
No author has any conflict of interest in respect to this work. LZ, LZ, XYJ, WW, KS, ATA, MQW, XSC, DZ, and JML have no disclosures to make. JWS has received research grants and honoraria from UCB, Eisai, and Janssen.
- 1.Gleichman AJ, Spruce LA, Dalmau J, Seeholzer SH, Lynch DR (2012) Anti-NMDA receptor encephalitis antibody binding is dependent on amino acid identity of a small region within the GluN1 amino terminal domain. J Neurosci 32(32):11082–11094. doi: 10.1523/jneurosci.0064-12.2012 CrossRefPubMedPubMedCentralGoogle Scholar
- 2.Dalmau J, Tuzun E, Wu HY, Masjuan J, Rossi JE, Voloschin A, Baehring JM, Shimazaki H, Koide R, King D, Mason W, Sansing LH, Dichter MA, Rosenfeld MR, Lynch DR (2007) Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 61(1):25–36. doi: 10.1002/ana.21050 CrossRefPubMedPubMedCentralGoogle Scholar
- 3.Zhang L, Wu MQ, Hao ZL, Chiang SM, Shuang K, Lin MT, Chi XS, Fang JJ, Zhou D, Li JM (2017) Clinical characteristics, treatments, and outcomes of patients with anti-N-methyl-D-aspartate receptor encephalitis: a systematic review of reported cases. Epilepsy Behav 68:57–65. doi: 10.1016/j.yebeh.2016.12.019 CrossRefPubMedGoogle Scholar
- 4.Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, Cortese I, Dale RC, Gelfand JM, Geschwind M, Glaser CA, Honnorat J, Hoftberger R, Iizuka T, Irani SR, Lancaster E, Leypoldt F, Pruss H, Rae-Grant A, Reindl M, Rosenfeld MR, Rostasy K, Saiz A, Venkatesan A, Vincent A, Wandinger KP, Waters P, Dalmau J (2016) A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15(4):391–404. doi: 10.1016/s1474-4422(15)00401-9 CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Titulaer MJ, McCracken L, Gabilondo I, Armangue T, Glaser C, Iizuka T, Honig LS, Benseler SM, Kawachi I, Martinez-Hernandez E, Aguilar E, Gresa-Arribas N, Ryan-Florance N, Torrents A, Saiz A, Rosenfeld MR, Balice-Gordon R, Graus F, Dalmau J (2013) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 12(2):157–165. doi: 10.1016/s1474-4422(12)70310-1 CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Pompili M, Amador XF, Girardi P, Harkavy-Friedman J, Harrow M, Kaplan K, Krausz M, Lester D, Meltzer HY, Modestin J, Montross LP, Mortensen PB, Munk-Jorgensen P, Nielsen J, Nordentoft M, Saarinen PI, Zisook S, Wilson ST, Tatarelli R (2007) Suicide risk in schizophrenia: learning from the past to change the future. Ann Gen Psychiatry 6:10. doi: 10.1186/1744-859x-6-10 CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Sakamoto H, Hirano M, Samukawa M, Ueno S, Maekura S, Fujimura H, Kuwahara M, Hamada Y, Isono C, Tanaka K, Kusunoki S, Nakamura Y (2013) Details of treatment-related difficulties in men with anti-N-methyl-D-aspartate receptor encephalitis. Eur Neurol 69(1):21–26. doi: 10.1159/000342023 CrossRefPubMedGoogle Scholar
- 23.Braun C, Bschor T, Franklin J, Baethge C (2016) Suicides and suicide attempts during long-term treatment with antidepressants: a meta-analysis of 29 placebo-controlled studies including 6,934 patients with major depressive disorder. Psychother Psychosom 85(3):171–179. doi: 10.1159/000442293 CrossRefPubMedGoogle Scholar
- 25.Erhardt S, Lim CK, Linderholm KR, Janelidze S, Lindqvist D, Samuelsson M, Lundberg K, Postolache TT, Traskman-Bendz L, Guillemin GJ, Brundin L (2013) Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology 38(5):743–752. doi: 10.1038/npp.2012.248 CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Dean B, Gibbons AS, Boer S, Uezato A, Meador-Woodruff J, Scarr E, McCullumsmith RE (2016) Changes in cortical N-methyl-D-aspartate receptors and post-synaptic density protein 95 in schizophrenia, mood disorders and suicide. Austr N Z J Psychiatry 50(3):275–283. doi: 10.1177/0004867415586601 CrossRefGoogle Scholar
- 29.Kjelby E, Sinkeviciute I, Gjestad R, Kroken RA, Loberg EM, Jorgensen HA, Hugdahl K, Johnsen E (2015) Suicidality in schizophrenia spectrum disorders: the relationship to hallucinations and persecutory delusions. Eur Psychiatry 30(7):830–836. doi: 10.1016/j.eurpsy.2015.07.003 CrossRefPubMedGoogle Scholar
- 31.Sher L, Fisher AM, Kelliher CH, Penner JD, Goodman M, Koenigsberg HW, New AS, Siever LJ, Hazlett EA (2016) Clinical features and psychiatric comorbidities of borderline personality disorder patients with versus without a history of suicide attempt. Psychiatry Res 246:261–266. doi: 10.1016/j.psychres.2016.10.003 CrossRefPubMedGoogle Scholar
- 34.Gresa-Arribas N, Titulaer MJ, Torrents A, Aguilar E, McCracken L, Leypoldt F, Gleichman AJ, Balice-Gordon R, Rosenfeld MR, Lynch D, Graus F, Dalmau J (2014) Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol 13(2):167–177. doi: 10.1016/s1474-4422(13)70282-5 CrossRefPubMedGoogle Scholar
- 35.Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, Dessain SK, Rosenfeld MR, Balice-Gordon R, Lynch DR (2008) Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 7(12):1091–1098. doi: 10.1016/s1474-4422(08)70224-2 CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes A, Hammad TA, Temple R, Rochester G (2009) Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 339:2880. doi: 10.1136/bmj.b2880 CrossRefGoogle Scholar